Dosage forms and therapeutic uses L-4-chlorokynurenine

• US 9,993,453 B2
• Filed: 02/08/2016
• Issued: 06/12/2018
• Est. Priority Date: 01/22/2013
• Status: Active Grant

• Current Assignee: VistaGen Therapeutics, Inc.
• Original Assignee: VistaGen Therapeutics, Inc.
• Inventors: Snodgrass, H. Ralph, Cato, Allen E., Hicklin, Jack S.
• Primary Examiner(s): CRUZ, KATHRIEN ANN
• Application Number:
  US15/018,219
• Publication Number:
  US 20160158178A1
• Time in Patent Office: 855 Days
• Field of Search: 514564
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.

Claims

1. A method of treating depression comprising the step of orally administering to a human patient in need thereof a therapeutically effective amount of L-4-chlorokynurenine, wherein the L-4-chlorokynurenine is administered in a daily dose of 360, 1080 or 1440 mg.

2. A method of claim 1, wherein the L-4-chlorokynurenine is administered in a pharmaceutical composition comprising L-4-chlorokynurenine and a pharmaceutically acceptable carrier or excipient.

3. A method of claim 1, wherein the L-4-chlorokynurenine is administered with no more than an adverse event that is easily tolerated by the patient, causing minimal discomfort and not interfering with everyday activities.

4. A method of claim 2, wherein the L-4-chlorokynurenine is administered with no more than an adverse event that is easily tolerated by the patient, causing minimal discomfort, and not interfering with everyday activities.

5. A method of claim 1, wherein the patient is administered L-4-chlorokynurenine daily from 1 to about 30 days.

6. A method of claim 1, wherein the patient is administered L-4-chlorokynurenine daily from about 7 to about 24 days.

7. A method of claim 1, wherein the patient is administered L-4-chlorokynurenine daily from about 12 to about 16 days.

8. A method of claim 2, wherein the patient is administered L-4-chlorokynurenine daily from 1 to about 30 days.

9. A method of claim 2, wherein the patient is administered L-4-chlorokynurenine daily from about 7 to about 24 days.

10. A method of treating depression comprising the step of orally administering to a human patient in need thereof a pharmaceutical composition comprising a unit dose of 360, 1080 or 1440 mg of L-4-chlorokynurenine and a pharmaceutically acceptable carrier or excipient.

11. A method of claim 10, wherein the L-4-chlorokynurenine is administered with no more than an adverse event that is easily tolerated by the patient, causing minimal discomfort, and not interfering with everyday activities.